iBio is an American biotechnology company. It focuses on development and commercialization of novel plant-made products for the prevention and treatment of serious infectious diseases. iBio is headquartered in New York.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
iBio news
13.05.2022
iBio's GAAP loss for 9 months of fiscal year 2022 was $33.25 million, up 42.5% from $23.327 million in the prior year. Revenue increased 23.5% to $2.322 million from $1.88 million a year earlier.
Source: 
ir.ibioinc.com
ir.ibioinc.com
15.02.2022
iBio's GAAP loss for 6 months of fiscal year 2022 was $20.86 million, up 33.2% from $15.665 million in the prior year. Revenue declined 2.9 times to $0.379 million from $1.115 million a year earlier.
Source: ir.ibioinc.com
ir.ibioinc.com
16.11.2021
iBio's GAAP loss for 3M 2022 fiscal year was $8.94 million, up 18.7% from $7.534 million in the prior year. Revenue declined 48.5% to $211,000 from $410,000 a year earlier.
Source: ir.ibioinc.com
ir.ibioinc.com
04.11.2021
iBio bought the remaining 30% of its subsidiary iBio CDMO, which holds the exclusive rights to manufacture drugs using the FastPharming system in the United States. iBio also purchased from Eastern Capital Limited a manufacturing facility whose facilities it had previously leased. iBio paid $28 million in cash and issued warrants to purchase 1,000,000 of its...
Source: ir.ibioinc.com
ir.ibioinc.com
General information
| Company name | iBio |
|---|---|
| Tags | #biotechnology |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 600 Madison Avenue Suite 1601 New York, NY 10022 United States |
| Mailing address | 600 Madison Avenue Suite 1601 New York, NY 10022 United States |
| Website | ir.ibioinc.com |
| Information disclosure | www.sec.gov |
English (US) 